GHK-Cu References and Citation Index

How to read these GHK-Cu references

These GHK-Cu references are the complete source list for the numbers reported across this site. Each inline [N] marker on the research, skin, hair, dosage and FAQ pages resolves to an entry below, with a DOI and a PubMed or PMC URL so any claim can be checked at the primary source. The list spans the foundational work — Maquart's 1988 fibroblast collagen study ^[1] and Pickart's tissue-remodeling and gene reviews ^[2][6] — through the 2024-2025 colitis, neuroprotection and anti-wrinkle literature ^[13][14][15]. The same citations underpin the GHK-Cu wound-healing research and the GHK-Cu safety and copper toxicity discussions elsewhere on the site.

Two cautions belong with the list. A large share of the foundational GHK-Cu mechanistic and review literature originates from a single investigator, Loren Pickart (1938-2023), and colleagues, so independent replication of the broader gene-expression and anti-aging claims is limited ^[2][6]. And the genome-wide signature is bioinformatic — derived largely from Connectivity Map analyses that still need protein-level in vivo validation ^[2]. The independent emphysema-gene-reversal ^[9] and the non-Pickart fibrosis ^[8], colitis ^[14] and neuroprotection ^[15] studies are noted here because they widen that evidentiary base.

Regulatory status of the cited compound

For context on the record below: there is no FDA- or EMA-approved therapeutic indication for GHK-Cu by any route. Topical Copper Tripeptide-1 is a legal cosmetic ingredient with a long safety record; injectable, oral and other systemic uses are unapproved and research-only ^[6]. One topical wound-healing trial (CuHeal, NCT07437586) has been registered, but there are no completed Phase 2/3 trials for systemic or injectable GHK-Cu. The references are the published research record — not evidence of an approved use.